Multiparametric Quantitative Ultrasound as a Potential Imaging Biomarker for Noninvasive Detection of Nonalcoholic Steatohepatitis: A Clinical Feasibility Study

多参数定量超声作为一种潜在的影像学生物标志物用于无创检测非酒精性脂肪性肝炎:一项临床可行性研究

阅读:1

Abstract

Objectives: The FibroScan-aspartate transaminase (AST) score (FAST score) is a hybrid biomarker combining ultrasound and blood test data for identifying nonalcoholic steatohepatitis (NASH). This study aimed to assess the feasibility of using quantitative ultrasound (QUS) biomarkers related to hepatic steatosis for NASH detection and to compare their diagnostic performance with the FAST score. Methods: A total of 137 participants, comprising 71 individuals with NASH and 66 with non-NASH (including 49 normal controls), underwent FibroScan and ultrasound exams. QUS imaging features (Nakagami parameter m, homodyned-K parameter μ, entropy H, and attenuation coefficient α) were extracted from backscattered radiofrequency data. A weighted QUS parameter based on m, μ, H, and α was derived via linear discriminant analysis. NASH was diagnosed based on liver biopsy findings using the nonalcoholic fatty liver disease activity score (NAS). Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUROC) and compared with the FAST score using the DeLong test. Separation metrics, including the complement of overlap coefficient, Bhattacharyya distance, Kullback-Leibler divergence, and silhouette score, were used to assess inter-group separability. Results: All QUS parameters were significantly elevated in NASH patients (p < 0.05). AUROC values for individual QUS features ranged from 0.82 to 0.91, with the weighted QUS parameter achieving 0.91. The FAST score had the highest AUROC (0.96), though differences with the weighted QUS and homodyned-K parameters were not statistically significant (p > 0.05). Separation metrics ranked the FAST score highest, closely followed by the weighted QUS parameter. Conclusions: QUS biomarkers can be repurposed for NASH detection, with the weighted QUS parameter offering diagnostic accuracy comparable to the FAST score and serving as a promising, blood-free alternative.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。